Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02860780
Title A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Eli Lilly and Company

lung non-small cell carcinoma

colon cancer

Advanced Solid Tumor


Prexasertib + Ralimetinib

Age Groups: adult | senior
Covered Countries USA | DEU

Additional content available in CKB BOOST